Delving into the Latest Updates on Bruschettini Srl with Synapse

概览

关联

1

项与 Bruschettini Srl 相关的药物

Tauroursodeoxycholate sodium

牛磺熊去氧胆酸

靶点

α5β1

作用机制

α5β1刺激剂

在研机构-

原研机构

Mitsubishi Tanabe Pharma Corp.

在研适应症-

非在研适应症

胆汁淤积性肝病 [+2]

最高研发阶段终止

首次获批国家/地区-

首次获批日期-

3

项与 Bruschettini Srl 相关的临床试验

NCT05753852 / Recruiting临床3期

Open Label Extension Study to Investigate Long Term Safety, Tolerability and Efficacy of Tauroursodeoxycholic Acid in Patients With ALS Who Completed the TUDCA-ALS Study

This study will provide extended access to patients and assess longer-term outcomes on patients who have completed the TUDCA-ALS study.

开始日期2021-10-25

申办/合作机构

Humanitas Mirasole SpA

[+9]

NCT03800524 / Active, not recruiting临床3期

Safety and Efficacy of Tauroursodeoxycholic (TUDCA) as add-on Treatment in Patients Affected by Amyotrophic Lateral Sclerosis (ALS)

This is a Phase III, multi-centre, randomized, double-blind, placebo-controlled, parallel-group study to evaluate Safety and Efficacy of Tauroursodeoxycholic (TUDCA) as add-on Treatment in Patients Affected by Amyotrophic Lateral Sclerosis (ALS).

开始日期2019-02-22

申办/合作机构

Humanitas Mirasole SpA

[+9]

EUCTR2011-003239-76-IT / Not yet recruitingN/A

Efficacy and tolerability clinical trial of Lantigen B (A bacterial lysate having immunostimulating activity) in the prophylaxis of respiratory infections, with special reference to patients with allergy to perennial inhalants. Double-blind multicenter, randomized study vs. placebo. - LAN-BR-11-001

开始日期2012-05-07

申办/合作机构

Bruschettini Srl

100 项与 Bruschettini Srl 相关的临床结果

登录后查看更多信息

0 项与 Bruschettini Srl 相关的专利（医药）

登录后查看更多信息

100 项与 Bruschettini Srl 相关的药物交易

登录后查看更多信息

100 项与 Bruschettini Srl 相关的转化医学

登录后查看更多信息